Merck agrees $11 billion deal for Prometheus
Merck & Co is to buy Prometheus Biosciences for about $10.8 billion, picking up a promising experimental treatment for ulcerative colitis and Crohn's disease and building up its presence in immunology.
Business
• 17 Apr 23
